Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Stocks in this Quantisnow insightHealth Care
Historical context for INBX
Across the 8 sessions after earlier INBX headlines, the stock closed higher 6 times and lower 2 times, with a median move of 6.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INBX | SPY |
|---|---|---|---|
| Apr 22, 2026 | Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer | +36.9% | +1.0% |
| Apr 8, 2026 | Stifel initiated coverage on Inhibrx Biosciences with a new price target | +7.7% | +2.5% |
| Mar 20, 2026 | Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | -6.1% | -1.7% |
| Mar 3, 2026 | Inhibrx Announces Participation in Upcoming Scientific Conference | -4.1% | -0.9% |
| Dec 17, 2025 | Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program | +1.9% | -1.1% |
| Nov 14, 2025 | Inhibrx Reports Third Quarter 2025 Financial Results | +6.0% | -0.0% |
Quantisnow market dataNASDAQ
INBX
Inhibrx Biosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for INBX
Full INBX profile on Quantisnow Follow INBX and get a push notification the moment its next story breaks.